ABL-301 is an antibody designed to inhibit alpha-synuclein pathology, which is a key mechanism involved in neurodegenerative diseases such as Parkinson's disease. By targeting alpha synuclein pathology, the therapeutic aims to reduce the spread of toxic alpha-synuclein aggregates in the brain.
Discover our Products
Science-based and high-quality devices
